Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Floorless Preferred Stock/Debenture -- Ignore unavailable to you. Want to Upgrade?

To: charles shaw who wrote (1013)	10/29/1999 12:31:00 AM
From: Dr. John M. de Castro	Respond to of 1438

Ariad strikes back! Is it possible that a company can escape the death grip of the toxic convertible. Tune in. It should be fascinating to watch the legal proceedings unfold. The outcome could be very significant for the death spiral convertible industry. ARIA was able to come up with the money through sale of assets to try for the buyback. Best regards John de C ARIAD Seeks Repurchase of Series C Preferred Stock ARIAD Agrees to Repurchase 2,000 Shares Held by Brown Simpson Funds and Files Lawsuit Against Promethean Investment Group and HFTP Investments CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct. 28, 1999-- ARIAD Pharmaceuticals, Inc. (Nasdaq: ARIA - news) today announced that it has entered into an agreement with Brown Simpson Strategic Growth Fund, Ltd. and Brown Simpson Strategic Growth Fund, L.P. to repurchase their 2,000 shares of ARIAD's series C preferred stock and other rights for an aggregate purchase price of $3,250,000, subject to certain closing conditions and price adjustments under certain circumstances. The closing is expected to occur during the fourth quarter of 1999. To facilitate the repurchase, the Brown Simpson funds agreed to forbear during the time prior to the closing from exercising certain rights under the series C purchase agreement, including the right to convert or redeem their preferred stock, the right to receive dividends, the right to purchase additional shares of series C preferred stock from ARIAD and the right to participate, through a right of first refusal, in future financings of ARIAD. The 2,000 shares of series C preferred stock were issued by ARIAD to the Brown Simpson funds in November 1998 for $2,000,000. Another 3,000 shares of series C preferred stock were issued to HFTP Investments, LLC, an affiliate of Promethean Investment Group, LLC, in November 1998 for $3,000,000. HFTP attempted earlier this month to convert certain of these shares of series C preferred stock into ARIAD common stock. Although ARIAD is in ongoing negotiations to repurchase these shares, on October 26, 1999, it filed an action in the United States District Court for the Southern District of New York entitled ARIAD Pharmaceuticals, Inc. v. Promethean Investment Group, LLC and HFTP Investments, LLC, C.A. No. 99-Civ-10794. ARIAD's complaint relies upon Promethean's admission of substantial short sales of ARIAD common stock prior to sending its conversion notice, and ARIAD alleges violations of the federal securities laws by Promethean and HFTP, including insider trading and stock manipulation through short sales, breach of contract and breach of the covenant of good faith and fair dealing, and is seeking an order enjoining defendants from further trading in ARIAD's common stock and damages in an amount to be determined at trial. One the same date, HFTP filed an action against ARIAD in the Chancery Court of the State of Delaware entitled HFTP Investments, LLC v. ARIAD Pharmaceuticals, Inc., C.A. No. 17501NC, alleging ARIAD's breach of contract for failure to convert certain shares of series C preferred stock into approximately 1.1 million shares of ARIAD common stock, and seeking an order requiring issuance of such shares and incidental damages in an amount specified in the certificate of designations for the series C preferred stock. To date, ARIAD has not converted any preferred shares due to the alleged wrongful activities of Promethean and HFTP.